金吾财讯 | 据外媒报道，诺和诺德(NVO)旗下热门减重药物Ozempic与WeGovy进驻美国超市好市多Costco(COST)，并以较便宜的价格出售。好市多会员凭医生处方购买有关药物，每月自付额为499美元，而Ozempic注射笔目前标价近1,000美元，WeGovy则约1,350美元。报道指，早前全国缺货期间，仿制药销量急升，集团此举是为了抵御竞争对手的冲击。集团美国业务总裁DavidMoore接受访问时表示，未来确实还有减价空间，但现阶段最重要的是扩大医疗保险的覆盖范围。
金吾财讯 | 据外媒报道，诺和诺德(NVO)旗下热门减重药物Ozempic与WeGovy进驻美国超市好市多Costco(COST)，并以较便宜的价格出售。好市多会员凭医生处方购买有关药物，每月自付额为499美元，而Ozempic注射笔目前标价近1,000美元，WeGovy则约1,350美元。报道指，早前全国缺货期间，仿制药销量急升，集团此举是为了抵御竞争对手的冲击。集团美国业务总裁DavidMoore接受访问时表示，未来确实还有减价空间，但现阶段最重要的是扩大医疗保险的覆盖范围。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.